About US
Contact us
-
DoJ hasn't given up on prosecuting execs for pharma misdoingsBy Tracy Staton Billions are rolling into the Justice Department off Big Pharma's fraud settlements. The recent GlaxoSmithKline ($GSK) deal, at $3 billion, broke Pfizer's ($PFE) previous record,2012/8/8
-
Top 11 Fastest-Growing Generics CompaniesBy Tracy Staton and Nesa Nourmohammadi For generics makers, Big Pharma's patent cliff is more like a mountain. With preparation and drive and some luck, companies that specialize in copycat drugs c2012/8/8
-
J&J acknowledges what everyone knows, it settled with DoJBuried deep in Thursday's quarterly report filing is Johnson & Johnson's ($JNJ) acknowledgement that it has an agreement to settle criminal cases brought by the Department of Justice and some stat2012/8/6
-
Generic savings tell a different patent-loss taleEarnings season has provided one measure of how hard patent losses and generic competition have hit pharma companies. The thousands and thousands of laid off workers is another gauge. But a new IMS st2012/8/6
-
SFDA issues the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012On July 20, 2012, the State Food and Drug Administration (SFDA) issued the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012.2012/8/3
-
2012’PhexTour pharmaceutical excipients application technology national tour seminar ——the sixth Harbin station has come to an end2012 PhexTour pharmaceutical excipients application technology national tour seminar the sixth station-Harbin, on July 27th, in Harbin Weiye hotel has come to an end. Nearly 20 local pharmaceutical2012/8/3
-
2012’PhexTour pharmaceutical excipients application technology national tour seminar ——the fifth Jinan station has come to an end2012 PhexTour pharmaceutical excipients application technology national tour seminar the fifth station-Jinan, on July 25th, in Jinan Minjuyihe international hotel has come to an end. Nearly 26 local2012/8/3
-
Bristol-Myers hep C trial hits the skids on safety concernsIn January, Bristol-Myers Squibb ($BMY) paid $2.5 billion for Inhibitex, jazzed by the prospects for its hepatitis C drug candidate. Now, 7 months later, that drug is in deep trouble. The company stop2012/8/3
-
Teva, Takeda boost profits as Valeant swings to lossTeva Pharmaceutical Industries ($TEVA) is the biggest fish in today's earnings pond. The generics giant--which now has a sizable footprint in branded drugs thanks to its Cephalon buyout--met expectati2012/8/3
-
U.K. drug spending down, scripts up on 'patent dividend'Want a statistical representation of the patent cliff's decidedly mixed blessings? The U.K. just released its latest report on drug spending. The gist is, costs are down but prescription numbers are u2012/8/2